Gilead Sciences, Boehringer Ingelheim and Takeda all recorded exits as immunotherapy developer Hookipa went public, floating at the bottom of its range.

Hookipa Pharma, the US-based immunotherapy developer backed by pharmaceutical firms Gilead Sciences, Takeda and Boehringer Ingelheim, has floated in an $84m initial public offering.

The company issued 6 million shares on the Nasdaq Global Select Market priced at $14 each, at the bottom of the IPO’s $14 to $16 range, valuing it at approximately $356m.

Hookipa is developing immunotherapies using its arenavirus platform, targeting infectious diseases and cancer, and is focusing on three lead product candidates.

HB-101 is intended to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn